title: Is it time to conclude that NMDA antagonists have failed?
authors.affiliation: GENOTOX Laboratory, Center for Biotechnology, Federal University of Rio Grande do Sul, Porto Alegre, Brazil. genotox@dna.cbiot.ufrgs.br <genotox@dna.cbiot.ufrgs.br>
authors.forename: Rafael
authors.initials: R
authors.lastname: Roesler
authors.forename: João
authors.initials: J
authors.lastname: Quevedo
authors.forename: Nadja
authors.initials: N
authors.lastname: Schröder
mesh_terms: D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy; D002986:Clinical Trials as Topic; D018691:Excitatory Amino Acid Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018696:Neuroprotective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D020521:Stroke / Q000188:drug therapy
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate